Cameron Santoro is an associate editor for The American Journal of Managed Care® (AJMC®), AJMC.com, and The Center for Biosimilars®.
Race and Immune Microenvironment Impacts on Breast Cancer Outcomes
Breast cancer outcomes are significantly impacted by race and immune responses, particularly among Black patients with triple-negative subtypes, emphasizing the need to understand these disparities and develop more effective treatment strategies.
EMBER-3 Trial: Imlunestrant Plus Abemaciclib Improves Survival in Advanced Breast Cancer
Komal Jhaveri, MD, FACP, breast oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center, presents findings from the EMBER-3 trial evaluating imlunestrant for patients with advanced breast cancer.
Elacestrant Shows Significant PFS Benefit in ESR1-Mutated Metastatic Breast Cancer
Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) compared with standard-of-care treatments for patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer.
Semaglutide Eligibility Expands to Over Half of US Adults
Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Targeted Therapies, Genomic Profiling Revolutionize Breast Cancer Treatment
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses the latest advancements in HR+/HER2– breast cancer research, as well as the increasing role of genomic profiling in tailoring treatment plans.